Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Company profile
Ticker
TEVA, TEVA-MM
Exchange
Website
CEO
Kaare Schultz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
Corporate docs
Subsidiaries
Actavis Group • Actavis International Limited • Actavis U.K. Group Ltd. • Arrow International Limited • Mepha Schweiz AG • Merckle GmbH • Pliva Hrvatska d.o.o. • Ratiopharm GmbH • Salomon, Levin & Elstein Ltd. • Teva API B.V. ...
TEVA stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
18 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
10-K
2023 FY
Annual report
12 Feb 24
8-K
Results of Operations and Financial Condition
31 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
8 Nov 23
8-K
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
4 Oct 23
8-K
Teva Announces Changes to Executive Management Team
28 Sep 23
Transcripts
TEVA
Earnings call transcript
2023 Q2
2 Aug 23
TEVA
Earnings call transcript
2023 Q1
10 May 23
TEVA
Earnings call transcript
2022 Q4
8 Feb 23
TEVA
Earnings call transcript
2022 Q2
27 Jul 22
TEVA
Earnings call transcript
2022 Q2
27 Jul 22
TEVA
Earnings call transcript
2022 Q1
3 May 22
TEVA
Earnings call transcript
2021 Q4
9 Feb 22
TEVA
Earnings call transcript
2021 Q3
27 Oct 21
TEVA
Earnings call transcript
2021 Q2
28 Jul 21
TEVA
Earnings call transcript
2021 Q1
28 Apr 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.25 bn | 2.25 bn | 2.25 bn | 2.25 bn | 2.25 bn | 2.25 bn |
Cash burn (monthly) | 140.00 mm | 666.67 k | (no burn) | 95.33 mm | (no burn) | (no burn) |
Cash used (since last report) | 955.08 mm | 4.55 mm | n/a | 650.36 mm | n/a | n/a |
Cash remaining | 1.29 bn | 2.25 bn | n/a | 1.60 bn | n/a | n/a |
Runway (months of cash) | 9.2 | 3368.2 | n/a | 16.8 | n/a | n/a |
Institutional ownership, Q3 2023
54.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 429 |
Opened positions | 54 |
Closed positions | 45 |
Increased positions | 129 |
Reduced positions | 128 |
13F shares | Current |
---|---|
Total value | 5.36 tn |
Total shares | 606.74 mm |
Total puts | 11.48 mm |
Total calls | 22.28 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Europacific Growth Fund | 52.75 mm | $813.41 mm |
BLK Blackrock | 40.78 mm | $415.99 bn |
Ion Asset Management | 38.82 mm | $395.99 bn |
PXGPE Phoenix | 34.48 mm | $351.71 bn |
Exor Investments | 33.85 mm | $345.27 bn |
Clal Insurance Enterprises | 30.61 mm | $309.02 bn |
Menora Mivtachim | 28.13 mm | $286.91 bn |
Harel Insurance Investments & Financial Services | 27.71 mm | $279.72 bn |
Migdal Insurance & Financial | 27.06 mm | $276.00 mm |
Slate Path Capital | 23.84 mm | $243.21 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | McAvoy David R. | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 66,964 | 0.00 | 66,964 |
4 Mar 24 | Christine Fox | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 81,845 | 0.00 | 81,845 |
4 Mar 24 | Angus Grant | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 52,083 | 0.00 | 52,083 |
4 Mar 24 | Vikki L Conway | Ordinary Shares | Sell | Dispose S | No | Yes | 13.3733 | 2,042 | 27.31 k | 11,692 |
4 Mar 24 | Vikki L Conway | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 7,117 | 0.00 | 13,734 |
4 Mar 24 | Vikki L Conway | Ordinary Shares | Sell | Dispose S | No | Yes | 13.3733 | 1,490 | 19.93 k | 6,617 |
4 Mar 24 | Vikki L Conway | Restricted Share Units Ordinary Shares | Grant | Acquire A | No | No | 0 | 33,482 | 0.00 | 33,482 |
4 Mar 24 | Vikki L Conway | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 7,117 | 0.00 | 14,237 |
3 Mar 24 | Vikki L Conway | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 5,179 | 0.00 | 8,107 |
3 Mar 24 | Vikki L Conway | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 5,179 | 0.00 | 15,538 |
News
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
22 Apr 24
'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo Finance
22 Apr 24
Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara
16 Apr 24
Teva's New Real-World Evidence Presented At The 2024 AAN Annual Meeting Confirms Effectiveness And Patient Satisfaction For HD Chorea With The 4-week Titration Kit For AUSTEDO Tablets
16 Apr 24
Reported Saturday, Teva Pharmaceuticals Presented New Pharmacokinetic Modeling Data By Simulates Clinical Profiles Of Schizophrenia Patients Switching To UZEDY® Extended-Release Injectable Suspension At SIRS 2024
8 Apr 24
Press releases
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16 Apr 24
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
11 Apr 24
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
9 Apr 24
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
6 Apr 24
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
4 Apr 24